ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Biogen Inc

Biogen Inc (BIIB)

217.81
-0.25
(-0.11%)
Closed May 25 4:00PM
217.81
0.00
(0.00%)
After Hours: 7:57PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
217.81
Bid
214.01
Ask
219.00
Volume
770,307
217.06 Day's Range 219.4421
189.44 52 Week Range 319.76
Market Cap
Previous Close
218.06
Open
218.21
Last Trade
20
@
218.95
Last Trade Time
Financial Volume
$ 168,074,432
VWAP
218.1915
Average Volume (3m)
1,228,017
Shares Outstanding
145,360,798
Dividend Yield
-
PE Ratio
27.27
Earnings Per Share (EPS)
7.99
Revenue
9.84B
Net Profit
1.16B

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vume... Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BIIB. The last closing price for Biogen was $218.06. Over the last year, Biogen shares have traded in a share price range of $ 189.44 to $ 319.76.

Biogen currently has 145,360,798 shares outstanding. The market capitalization of Biogen is $31.66 billion. Biogen has a price to earnings ratio (PE ratio) of 27.27.

Biogen (BIIB) Options Flow Summary

Overall Flow

Bearish

Net Premium

-873k

Calls / Puts

200.00%

Buys / Sells

85.71%

OTM / ITM

42.11%

Sweeps Ratio

0.00%

BIIB Latest News

OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News

News Corp (NASDAQ:NWS) – News Corp and OpenAI have established a historic partnership allowing OpenAI to use journalistic content from News Corp, including major titles like The Wall Street...

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an...

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis...

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis PR Newswire CARLSBAD, Calif. and CAMBRIDGE, Mass., May 16, 2024 Development of...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast...

Biogen Reports Progress on Corporate Responsibility Priorities

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq:...

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA PR...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-11.61-5.06058756865229.42232.75217.06936663226.2037374CS
416.598.24470728556201.22236.9199.11123104221.55881815CS
120.350.160949140072217.46236.9189.441228017213.9328383CS
26-13.44-5.81189189189231.25268.74189.441173003227.73211669CS
52-84.01-27.8344708767301.82319.76189.441106163246.52499118CS
156-67.79-23.7359943978285.6468.2499187.161238813264.72418468CS
260-11.92-5.188699778229.73468.2499187.161370450269.7812649CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

BIIB Discussion

View Posts
avxl_going_long avxl_going_long 2 weeks ago
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
👍️0
Monksdream Monksdream 2 months ago
BIIB still in bear mode
👍️0
Lonewolf1 Lonewolf1 1 year ago
Oops…. Another HOD


$10
👍️0
MiamiGent MiamiGent 1 year ago
BIIB Took a little short AH when it's PDUFA decision was mixed
Shorted at 261.50
Closed out AH at 260.87
Not expecting more than a hamburger and fries. BIOGEN INC is huge company and hard to move its dial.

https://stockcharts.com/h-sc/ui?s=BIIB
👍️0
Mr. Zen Mr. Zen 1 year ago
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
👍️0
Mr. Zen Mr. Zen 1 year ago
This board is about to light up!
👍️0
tredenwater2 tredenwater2 1 year ago
Well Biib and Esaly look to be joined at the hip. And here I thought they were two profitable independent companies. Amazing how they have traded virtually identical as if this is their only ticket left to punch.

And why no run up? Is the gig finally up Mc? Maybe their MM “cried wolf” one too many times.
👍️0
McMagyar McMagyar 1 year ago
Who wants to be the lead Buffalo today?
Can you stampede the herd of bio thieves over the $30Billion dollar cliff for the fourth time? Maybe! But you are stealing from treatments and patients and all those who love them.. for nothing..
The best aduscam will ever be is an adjuvant to anavex or cassava..

The BEST..

Don’t do it again .. even if you can..

Please
👍️0
tredenwater2 tredenwater2 1 year ago
Funds swapping spit again, nothing new.
👍️0
McMagyar McMagyar 1 year ago
Imagine if fda had denied?
Pyrrhic Victory defined
👍️0
tredenwater2 tredenwater2 1 year ago
Amen MC. Im surprised at only a 3.5% rise in pps. Wheres the 10-20 billion MC increase enthusiasm like 4 times before? Maybe they will have to PR it again in a week so the market “gets it”.
👍️0
McMagyar McMagyar 1 year ago
Ps not short Biogen..
Just long dementia
👍️ 1
McMagyar McMagyar 1 year ago
Investors can make a difference as to what our healthcare system becomes..

You and your decisions affect millions of lives..

Let Blarcamesine , succesful TLD ,
Be the rule of the day for our sick..

See if other drugs help people once their homeostasis is secured..maybe in smaller doses as an adjuvant ..

Anavex’s Blarcamesine works
👍️0
McMagyar McMagyar 1 year ago
If you will give a healthy 5 year old an experimental mRNA drug which creates toxic spike proteins in their system..by design! Nonetheless, why wouldn’t you give death sentenced dementia patients a dangerous possibly brain swelling drug that does almost nothing?

The system is broken
👍️0
McMagyar McMagyar 1 year ago
This will be the last chance to extricate your financial future from bioscam
And invest in one of these :
Anavex
Cassava
Annovis

Biovie

In that order of magnitude per solution and timing ..in my humble opinion

Or all four..
👍️0
tredenwater2 tredenwater2 1 year ago
Will Biogen drop like a rock by or shoot up by 10 billion come Friday? FDA is in a pickle here. Is there an advisory panel this go around or is this who will weigh in come Friday?
👍️0
tredenwater2 tredenwater2 1 year ago
What a scam! Older article but will take afew years to play out Im sure.
👍️0
tradeherpete tradeherpete 1 year ago
Biogen Accused of Baiting Patients With Illegal Drug Co-Pays
ByRobert Burnson
September 24, 2021, 9:57 PM EDT

Biogen Inc. was accused by a managed-care provider of illegally boosting sales of its pricey multiple sclerosis drugs by providing them free to patients on a temporary basis and then funneling money to them for co-payments so they can keep taking the medications.

The first part of the scheme involves “seeding” the drugs -- Tysabri, Avonex, and Tecfidera -- to multiple sclerosis sufferers who lacked medical insurance, according to the lawsuit filed Friday by Humana Inc.

After a few months, Biogen encourages the patients to sign up for government-funded healthcare and then funnels “illegal copayment assistance to those same patients under the guise of unrestricted charitable giving,” Humana said.

The money is funneled through a large specialty pharmacy and two medical charities who provide co-pay assistance, according to the suit.

“Given the high costs of the MS drugs here, copays can be thousands of dollars for any single patient,” Humana says in the suit.“But they are a tiny fraction of the total expense for the drugs. This means that if the manufacturer pays the copays itself, it can earn a major return from a minor investment.”

The drugs cost $50,000 to $80,000 a year, according to the suit.

Biogen didn’t respond after regular business hours to a request for comment.
👍️0
Dennisb68 Dennisb68 1 year ago
RGEN is on a run while Biogen is stalled.. Both similar companies,
👍️0
jgrabar jgrabar 1 year ago
https://www.marketwatch.com/press-release/grabar-law-office-investigates-claims-on-behalf-of-shareholders-of-biogen-inc-biib-after-it-agrees-to-pay-900-million-for-improper-physician-payments-2022-11-30?siteid=bigcharts&dist=bigcharts&tesla=y
👍️0
tredenwater2 tredenwater2 1 year ago
Unlike the patients heads, the share price “swelling” for Biogen always goes down. Another difference is Biogens Alzheimer’s amyloid platform never dies, just a few of their patients here and there in their trials.

Alzheimer’s is tough, didnt you know, just a little collateral damage, now hurry up and give me approval!
👍️0
McMagyar McMagyar 1 year ago
How does this dead dog bounce?
On swelled brains of course
👍️0
blackpilled blackpilled 2 years ago
One last dance?
👍️0
McMagyar McMagyar 2 years ago
Wouldnt touch bioscam
But agree seller salmoat out
👍️0
conix conix 2 years ago
Biogen (NASDAQ:BIIB) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $265.00 price target on the stock, up previously from $235.00.This represents a 23.7% upside from the current price of $214.28

---- Biotechs are due for a run soon....jmo
👍️0
McMagyar McMagyar 2 years ago
Phase 4. How many must suffer to pave the linings? When anavex has safe and proved drug available now?
How hateful the crews that say they care about human beings suffering dementia..

You don’t give a shit
👍️0
McMagyar McMagyar 2 years ago
Can you imagine the poor bastards that listened to Corey Renauer of motley fool when he said sell Anavex and buy Biogen a few years back?
Can they sue anyone?

What a cruel and twisted effort that was
👍️0
McMagyar McMagyar 2 years ago
All the resources these pumpers stole from legitimate chances to save people with dementia..

How much quicker Anavex and others could have moved without this blockaded fraud in their way..

Oxygen and money hole from hell
👍️0
McMagyar McMagyar 2 years ago
Thought they were getting bought out today?

What’s worse is

They knew who anavex was and blew up a chance at a deep relationship through what appears to be a poorly handled MTA ..

Still waiting for Wayne State.. pathetic really..

Arrogance and power smell worse than week old sub Saharan carrion..
👍️0
tredenwater2 tredenwater2 3 years ago
Another pump and dump, this time on approval of their drug of all things! Wow, when even approval doesnt work there is some real bad mojo working against you. 3rd or 4 rth cycle of 20 billion that has come and gone. The HFs that own BIIB are making a killing, no pun intended!
👍️0
AAAAMHIM AAAAMHIM 3 years ago
$BIIB NEWS!!!! Fasten your SEATBELTS!???????
https://finance.yahoo.com/news/biogen-plans-initiate-phase-3b-113000162.html
👍️0
EHRjunkie EHRjunkie 3 years ago
Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on

https://www.accesswire.com/viewarticle.aspx?id=663682
👍️0
tredenwater2 tredenwater2 3 years ago
Laughable, the pps is one step away from giving up all the fake gains from the announcement of Fda approval for their drug which is still not shown to be efficacious and can be highly toxic for patients including but not limited to death.

OAN Im a little surprised that ihub only allows investors to go back 1 year on the charting….. what gives? Those that forget history are more likely to repeat it. Case in point, I was trying to go back 5 years and look at how Biogen has been overhyped now 3 times for the very close to the exact same amount and has given it all back 2 of the 3 and soon to be 3 for 3 times.

Just an observation.

👍️0
mrplmer mrplmer 3 years ago
Pps down $120+ after pumping their bad meds which have no efficacy. Eisai has to break away or go down with the liars. Japanese dont like the bad rep.
👍️0
conix conix 3 years ago

STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

By Ed Silverman



The 15-to-0 vote on the Alzheimer's drug Aduhelm amounted to a rebuke of both Biogen and the Food and Drug Administration.
👍️0
Pioneer10257 Pioneer10257 3 years ago
Biogen's Aduhelm stumbles at the starting blocks.

https://endpts.com/major-health-systems-refuse-to-administer-aduhelm-as-top-fda-leaders-meet-behind-closed-doors-to-talk-with-payers/
👍️0
AAAAMHIM AAAAMHIM 3 years ago
$BIIB WEEEEEEEEE!!
👍️0
Chilean spy Chilean spy 3 years ago
Hi Mrplmer
This company's lack of evidence for it's drug' safety and effectiveness should plunge the stock to nothing I wonder what s keeping it on the 300 hundreds. Everyday's bad news around then and it keeps going up ?
👍️0
mrplmer mrplmer 3 years ago
It doesntcome close to Anavex results.
👍️0
AAAAMHIM AAAAMHIM 3 years ago
CLOSED EXTREMELY BULLISH INTO close and afterhours. I wouldnt wanna be a short tomorrow.

Listen to a $BIIB patient who's A DOCTOR! MUST WATCH VIDEO. DRUG WORKS! Poor shorts lost their ONLY ammo to bash it. Their KEY bash has expired, now they're reaching for anything. $BIIB can run for a full week+ shorts will lose houses here. Will run $600+.
https://t.co/1xX3cNoMCk
👍️0
mrplmer mrplmer 3 years ago
Down 100 pts since they released the dog. FDA needs to redeem themselves from passing on this POS onto the public.
👍️0
tradeherpete tradeherpete 3 years ago
The fallout has already been widespread. So far, three members of the FDA’s advisory committee have resigned, one of them calling the process a “sham.” Doctors who helped run Biogen’s clinical studies are speaking out, and others are penning editorials that they won’t be prescribing Aduhelm until they see evidence of effectiveness. But no one should hold their breath. When the FDA greenlit Aduhelm for use, it told Biogen it had nine years to run the confirmatory studies necessary to prove Aduhelm’s effectiveness. Nine years of people taking this drug that existing data suggests might not do anything meaningful. With Aduhelm poised to become among the biggest blockbuster drug in history—analysts estimate annual revenues could peak at $10 billion—Biogen probably isn’t in a hurry. But they might not even have to collect that extra data at all (for its part, Biogen said in an email to Slate, “We are working diligently to initiate the confirmatory trial”). Ross, the Yale FDA regulatory expert, looked at FDA approvals from 2005–12, and found that post-market confirmatory studies—ones that truly verified the clinical value of a surrogate outcome—only took place about 10 percent of the time. Despite this dismal compliance rate, according to Ross, the FDA has never fined a company for failing to do a confirmatory study and rarely uses its power to withdraw a drug later shown to be clinically ineffective. In an email to Slate, the FDA did not offer comment on whether it would use its power to withdraw Aduhelm should the drug ultimately prove clinically ineffective but “will carefully monitor trial progress and support efforts to complete this trial in the shortest possible timeline.”

https://slate.com/technology/2021/06/alzheimers-drug-aduhelm-fda-outcomes-plaques.amp
👍️0
polarbear77 polarbear77 3 years ago
https://slate.com/technology/2021/06/alzheimers-drug-aduhelm-fda-outcomes-plaques.amp

#pathetic

👍️0
mrplmer mrplmer 3 years ago
This is a POS. Puts lipstick on pigs and makes drugs that cause brain bleeds.
👍️0
hebbeke47 hebbeke47 3 years ago
https://endpts.com/new-alzheimers-drug-approval-fallout-public-citizen-seeks-removal-of-fdas-woodcock-cavazzoni-and-dunn/
👍️0
Cbdpotential Cbdpotential 3 years ago
https://www.facebook.com/752348178140245/posts/4973596112682076/?d=n
👍️0
Cbdpotential Cbdpotential 3 years ago
http://bit.ly/2O37FjH
👍️0
Cbdpotential Cbdpotential 3 years ago
https://pubmed.ncbi.nlm.nih.gov/34110944/
👍️0
jessellivermore jessellivermore 3 years ago
CBD...

I am not a short seller and hold no short position in this stock..I have no idea what your background is..I am a healthcare professional an MD with a interest in the history of medicine..

The history of medicine was framed nicely by an old professor of mine..

"In medicine the questions don't change only the answers."

Medical science has advanced by errors and misconceptions which continue until this very day, Ambrose Pare was a French "Barber Surgeon" in the middle ages..In his time gunshot wounds of the legs were treated by immersing the amputation stump in boiling oil..The rationale was not (as some of my comrade surgeons imagine) to stop the bleeding..Bleeding from the major leg vessels required tying off the vessels then as is still the case. The boiling oil emersion was done because the thinking in those days that gun powder was toxic and cause tetanus and gangrene. The oil imersion was done after the vessels were ligate and the bleeding stopped. Pare was fairly busy one day and performed 21 amputations. Later he was told they had no available boiling oil. Pare went to bed that night with a heavy heart.he was convinced all his patients would be dead in the morning. To his surprise he found his patients were doing better than usual, Usual being temperatures of 105 degrees.. He thought it was a miracle..

In 1934 the Nobel Prize in medicine was awarded to Minot and Murphy for discovering the treatment of Pernicious Anemia (rampant in the early 20thcentury). Minot and Murphy were awarded the prize by identifying Folic Acid as the deficiency in PA...Turns out Folic Acid deficiency was not the cause of PA, Later on William Castle(one of my professors) proved the true cause was Vit B12...Castle never got the Nobel Prize. These stories are rampant in the history of medicine...Yes we see tangles in AD..but what do they mean and how does it work?...

AD is a disease relating to aging..To my way of thinking most every condition seen in aging is related to the degree of systemic inflammation..The higher your basal inflammatory levels are, the faster you age and I do not see AZ as an outlier..Want to slow down AD..cut down on your systemic inflammation.

":>) JL
👍️0
jessellivermore jessellivermore 3 years ago
Cbd...

Quote..." The causes are known...Check Anavex studies and chromatin structures.."

Take it up with Eli Lilly

":>) JL
👍️0

Your Recent History

Delayed Upgrade Clock